Synonym
SRX-246; SRX246; SRX 246; API-246; API246; API 246;
IUPAC/Chemical Name
(2R)-4-([1,4'-bipiperidin]-1'-yl)-4-oxo-2-((3S,4R)-2-oxo-3-(2-oxo-4-phenyloxazolidin-3-yl)-4-((E)-styryl)azetidin-1-yl)-N-((R)-1-phenylethyl)butanamide
InChi Key
FJUKOXWSIGULLE-ZEULCVOWSA-N
InChi Code
InChI=1S/C42H49N5O5/c1-30(32-16-8-3-9-17-32)43-40(49)36(28-38(48)45-26-22-34(23-27-45)44-24-12-5-13-25-44)46-35(21-20-31-14-6-2-7-15-31)39(41(46)50)47-37(29-52-42(47)51)33-18-10-4-11-19-33/h2-4,6-11,14-21,30,34-37,39H,5,12-13,22-29H2,1H3,(H,43,49)/b21-20+/t30-,35-,36-,37?,39+/m1/s1
SMILES Code
O=C(N[C@@H](C1=CC=CC=C1)C)[C@H](N2C([C@@H](N3C(OCC3C4=CC=CC=C4)=O)[C@H]2/C=C/C5=CC=CC=C5)=O)CC(N6CCC(N7CCCCC7)CC6)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
703.88
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Fabio KM, Guillon CD, Lu SF, Heindel ND, Brownstein MJ, Lacey CJ, Garippa C, Simon NG. Pharmacokinetics and metabolism of SRX246: a potent and selective vasopressin 1a antagonist. J Pharm Sci. 2013 Jun;102(6):2033-43. doi: 10.1002/jps.23495. Epub 2013 Mar 7. PubMed PMID: 23471831.
2: Fabio K, Guillon C, Lacey CJ, Lu SF, Heindel ND, Ferris CF, Placzek M, Jones G, Brownstein MJ, Simon NG. Synthesis and evaluation of potent and selective human V1a receptor antagonists as potential ligands for PET or SPECT imaging. Bioorg Med Chem. 2012 Feb 1;20(3):1337-45. doi: 10.1016/j.bmc.2011.12.013. Epub 2011 Dec 20. PubMed PMID: 22249122; PubMed Central PMCID: PMC3449305.
3: Lee RJ, Coccaro EF, Cremers H, McCarron R, Lu SF, Brownstein MJ, Simon NG. A novel V1a receptor antagonist blocks vasopressin-induced changes in the CNS response to emotional stimuli: an fMRI study. Front Syst Neurosci. 2013 Dec 12;7:100. doi: 10.3389/fnsys.2013.00100. eCollection 2013 Dec 12. PubMed PMID: 24376401; PubMed Central PMCID: PMC3859978.
